CXCL9 and neoplasm: Taking into account the previous discovery of Cxcl9 and Cxcl10 as upregulated DEGs and the pathway enrichment results, we inferred that in NSCLC treated with ICB combination therapy, the production of Cxcl9 and Cxcl10 in the tumor microenvironment promotes the infiltration of CD8+ T cells [34] and helps in the progression of ‘hot’ tumors [35].